Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.58 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.58 |
| ▸ | ANPEP | P15144 | 1/20 | 0.56 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | NTSR2 | O95665 | 4/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.51 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.51 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29706298 | 0.97 | SLC6A2 (0.59) | SLC6A2AGTR2AGTR1ANPEPLNPEP | |
| SCHEMBL29706275 | 0.95 | SLC6A2 (0.57) | SLC6A2AGTR2AGTR1OPRM1OPRD1 | |
| SCHEMBL29706479 | 0.95 | SLC6A2 (0.57) | SLC6A2AGTR2AGTR1OPRM1OPRD1 | |
| SCHEMBL29706203 | 0.93 | MAPK8 (0.56) | SLC6A2AGTR2AGTR1OPRM1OPRD1 | |
| SCHEMBL29706204 | 0.93 | SLC6A2 (0.54) | SLC6A2AGTR2AGTR1ANPEPLNPEP | |
| SCHEMBL29706382 | 0.92 | SLC6A2 (0.53) | SLC6A2AGTR2AGTR1NTSR2NTSR1 | |
| SCHEMBL29706182 | 0.92 | SLC6A2 (0.53) | SLC6A2AGTR2AGTR1NTSR2NTSR1 | |
| SCHEMBL29706238 | 0.90 | MAPK8 (0.55) | SLC6A2AGTR2AGTR1ANPEPLNPEP | |
| SCHEMBL29706231 | 0.90 | SLC6A2 (0.52) | SLC6A2AGTR2AGTR1OPRM1OPRD1 | |
| SCHEMBL30688081 | 0.89 | NTSR2 (0.60) | SLC6A2AGTR2AGTR1ANPEPLNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118946593-A | Insulin hybrid peptide containing chymotrypsin inhibitory peptide and application thereof | 中国医学科学院药物研究所 | 2024-11-12 | — | — | CN | disclosed |
| US-20230416329-A1 | A PEPTIDE WITH DISULFIDE BONDS AND INHIBITORY ACTIVITY AGAINST SERINE PROTEASES, DERIVED HYBRID PEPTIDES THEREOF, AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2023-12-28 | — | — | US | disclosed |
| CN-117186237-A | Insulin hybrid peptide containing chymotrypsin inhibitory peptide and application thereof | 中国医学科学院药物研究所 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023231969-A1 | INSULIN HYBRID PEPTIDE COMPRISING CHYMOTRYPSIN INHIBITORY PEPTIDE, AND USE THEREOF | 中国医学科学院药物研究所 | 2023-12-07 | — | — | WO | disclosed |
| CN-116615436-A | Disulfide bond-containing polypeptide with serine protease activity inhibiting function, hybrid peptide derived from disulfide bond-containing polypeptide and application of disulfide bond-containing polypeptide | 中国医学科学院药物研究所 | 2023-08-18 | — | — | CN | disclosed |
| WO-2022111713-A9 | POLYPEPTIDE CONTAINING DISULFIDE BONDS AND CAPABLE OF INHIBITING ACTIVITY OF SERINE PROTEASE, DERIVED HYBRID PEPTIDE THEREOF, AND USE THEREOF | 中国医学科学院药物研究所 | 2023-07-27 | — | — | WO | disclosed |
| CN-114573686-A | Polypeptide containing disulfide bond and having serine protease activity inhibition function and application thereof | 中国医学科学院药物研究所 | 2022-06-03 | — | — | CN | disclosed |
| WO-2022111713-A1 | POLYPEPTIDE CONTAINING DISULFIDE BONDS AND CAPABLE OF INHIBITING ACTIVITY OF SERINE PROTEASE, DERIVED HYBRID PEPTIDE THEREOF, AND USE THEREOF | 中国医学科学院药物研究所 | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416329-A1 | A PEPTIDE WITH DISULFIDE BONDS AND INHIBITORY ACTIVITY AGAINST SERINE PROTEASES, DERIVED HYBRID PEPTIDES THEREOF, AND USES THEREOF | VIP, SI, TMPRSS15 | SLC6A2 2974/4885AGTR2 2324/4885AGTR1 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.